ZA200308270B - Liposome composition for improved intracellular delivery of a therapeutic agent. - Google Patents

Liposome composition for improved intracellular delivery of a therapeutic agent.

Info

Publication number
ZA200308270B
ZA200308270B ZA200308270A ZA200308270A ZA200308270B ZA 200308270 B ZA200308270 B ZA 200308270B ZA 200308270 A ZA200308270 A ZA 200308270A ZA 200308270 A ZA200308270 A ZA 200308270A ZA 200308270 B ZA200308270 B ZA 200308270B
Authority
ZA
South Africa
Prior art keywords
therapeutic agent
intracellular delivery
liposome composition
improved intracellular
improved
Prior art date
Application number
ZA200308270A
Other languages
English (en)
Inventor
Samuel Zalipsky
Shi Kun Huang
Theresa M Allen
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA200308270B publication Critical patent/ZA200308270B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
ZA200308270A 2001-03-26 2003-10-23 Liposome composition for improved intracellular delivery of a therapeutic agent. ZA200308270B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27886901P 2001-03-26 2001-03-26

Publications (1)

Publication Number Publication Date
ZA200308270B true ZA200308270B (en) 2005-02-25

Family

ID=23066719

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200308270A ZA200308270B (en) 2001-03-26 2003-10-23 Liposome composition for improved intracellular delivery of a therapeutic agent.

Country Status (12)

Country Link
US (2) US7108863B2 (ja)
EP (1) EP1385479A4 (ja)
JP (1) JP2004525138A (ja)
CN (1) CN1294991C (ja)
AU (1) AU2002305094B2 (ja)
CA (1) CA2442261A1 (ja)
HU (1) HUP0303616A3 (ja)
IL (1) IL158160A0 (ja)
MX (1) MXPA03008864A (ja)
NZ (1) NZ528523A (ja)
WO (1) WO2002076428A1 (ja)
ZA (1) ZA200308270B (ja)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2004089419A1 (ja) * 2003-04-04 2004-10-21 The University Of Tokyo 抗ｍｔ－ｍｍｐモノクローナル抗体含有脂質膜構造体
US7216038B2 (en) 2003-09-11 2007-05-08 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US7219017B2 (en) 2003-09-11 2007-05-15 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US7219018B2 (en) * 2003-09-11 2007-05-15 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
EP4218730B1 (en) 2004-05-03 2023-11-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN101023123A (zh) * 2004-08-31 2007-08-22 株式会社奥西珍尼克斯 薄膜状高分子结构体及其制备方法
US20070014845A1 (en) * 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
JP2009506188A (ja) 2005-08-30 2009-02-12 エイジェンシー フォー サイエンス， テクノロジー アンド リサーチ 絡み合った蛍光ポリマーおよび両親媒性分子を含んだ水溶性蛍光粒子
CA2628300C (en) 2005-11-02 2018-04-17 Protiva Biotherapeutics, Inc. Modified sirna molecules and uses thereof
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
WO2008008523A1 (en) * 2006-07-14 2008-01-17 Regents Of The University Of Minnesota COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE
ES2553193T3 (es) 2006-10-27 2015-12-04 Shinji Takeoka Estructura polimérica similar a una película delgada y método para preparar la misma
EP2494993B1 (en) 2007-05-04 2018-08-01 Marina Biotech, Inc. Amino acid lipids and uses thereof
WO2008139457A2 (en) * 2007-05-10 2008-11-20 Clear Direction Ltd. Methods and compositions for drug targeting
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
US9789194B2 (en) 2007-11-27 2017-10-17 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
US9271933B2 (en) * 2007-11-27 2016-03-01 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
EP4053546A1 (en) 2007-12-06 2022-09-07 Genalyte, Inc. Device and method for performing label-free monitoring of processes.
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
US20110038941A1 (en) * 2007-12-27 2011-02-17 The Ohio State University Research Foundation Lipid Nanoparticle Compositions and Methods of Making and Using the Same
KR101004709B1 (ko) 2007-12-28 2011-01-04 강원대학교산학협력단 글루코스 산화효소가 고정화된 베시클의 제조방법
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
EP2770057A1 (en) 2008-04-15 2014-08-27 Protiva Biotherapeutics Inc. Silencing of CSN5 gene expression using interfering RNA
WO2010045512A2 (en) 2008-10-16 2010-04-22 Mdrna , Inc. Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
JP5656853B2 (ja) 2008-10-27 2015-01-21 ジェナリーテ， インコーポレイテッド 光学的な探査及び検知に基づくバイオセンサ
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
US20120237589A1 (en) * 2009-07-09 2012-09-20 Marina Biotech, Inc. Amphoteric liposomes comprising imino lipids
KR101346197B1 (ko) * 2009-07-17 2014-02-06 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
US9921165B2 (en) 2010-11-05 2018-03-20 Genalyte, Inc. Optical analyte detection systems and methods of use
CA2826594C (en) 2011-02-03 2019-09-17 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
WO2013014073A1 (en) * 2011-07-22 2013-01-31 Universite De Strasbourg Phospholipid-detergent conjugates and uses thereof
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
MX2014010016A (es) 2012-02-21 2015-06-05 Inst Nat Sante Rech Med Receptores de mucina de inmunoglobulina de celula t (tim) como co-factores de entrada del virus.
BR112014021065A8 (pt) 2012-02-21 2018-04-24 Centre Nat Rech Scient receptores tam como cofatores de entrada do vírus
WO2013138251A1 (en) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Optical analyte detection systems with magnetic enhancement and methods of use
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
JP6302560B2 (ja) 2013-12-20 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法
JP6629736B2 (ja) 2013-12-20 2020-01-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む、細胞を結合するのに有用な化合物
CA2929972C (en) 2013-12-20 2018-07-24 F. Hoffmann-La Roche Ag Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell
US9457041B2 (en) 2014-06-20 2016-10-04 Ndsu Research Foundation Controlled release nanoparticles and methods of use
SG11201702662UA (en) 2014-10-02 2017-04-27 Protiva Biotherapeutics Inc Compositions and methods for silencing hepatitis b virus gene expression
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
CN116212048A (zh) 2015-08-12 2023-06-06 麻省理工学院 纳米颗粒的细胞表面偶联
AU2016309002B2 (en) 2015-08-20 2021-07-29 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
AU2016310476B8 (en) 2015-08-21 2021-10-07 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
US11696959B2 (en) * 2015-12-31 2023-07-11 City Of Hope Nanoparticle-cell construct with platinum anti-cancer agent
JP7071933B2 (ja) 2016-02-25 2022-05-19 アプライド バイオロジカル ラボラトリーズ インコーポレイテッド 浮遊病原体および刺激物に対して防御するための組成物および方法
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP4104854A3 (en) 2016-04-04 2023-03-08 The United States of America as represented by the Secretary of the Department of Health and Human Services Multivalent vaccines for rabies virus and coronaviruses
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN106309370A (zh) * 2016-09-20 2017-01-11 上海上药新亚药业有限公司 一种紫杉醇pH敏长循环脂质体及其制备方法
WO2018083470A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
EP3713603A1 (en) 2017-11-23 2020-09-30 Institut National de la Sante et de la Recherche Medicale (INSERM) New method for treating dengue virus infection
PE20212366A1 (es) * 2019-03-29 2021-12-21 Glycomine Inc Formulaciones liposomales y metodos de uso y preparacion de las mismas
US20230000929A1 (en) 2019-11-26 2023-01-05 Board Of Regents, The University Of Texas System Bdellovibrio treatment for amyotrophic lateral sclerosis
CN114010600B (zh) * 2020-04-10 2022-08-23 浙江大学 一种酶促阳离子化脂质材料及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
AU4907897A (en) * 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
IL146047A0 (en) 1999-04-23 2002-07-25 Alza Corp Releasable linkage and compositions containing same
MXPA01010750A (es) * 1999-04-23 2003-08-20 Alza Corp Conjugado que tiene un enlace dividible para utilizarse en un liposoma.

Also Published As

Publication number Publication date
US20020192275A1 (en) 2002-12-19
US20060240009A1 (en) 2006-10-26
CA2442261A1 (en) 2002-10-03
MXPA03008864A (es) 2004-12-06
EP1385479A1 (en) 2004-02-04
AU2002305094B2 (en) 2007-01-11
HUP0303616A3 (en) 2006-07-28
CN1294991C (zh) 2007-01-17
HUP0303616A2 (hu) 2004-05-28
US7108863B2 (en) 2006-09-19
WO2002076428A1 (en) 2002-10-03
JP2004525138A (ja) 2004-08-19
EP1385479A4 (en) 2006-12-06
AU2002305094C1 (en) 2002-10-08
CN1509166A (zh) 2004-06-30
IL158160A0 (en) 2004-03-28
NZ528523A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
ZA200308270B (en) Liposome composition for improved intracellular delivery of a therapeutic agent.
GB0108228D0 (en) Medicament dispenser
GB0108213D0 (en) Medicament dispenser
GB0114175D0 (en) Medicament dispenser
EP1416884A4 (en) DISTRIBUTION OF AGENTS WITH THERAPEUTIC PROPERTIES
GB0108215D0 (en) Medicament dispenser
GB0108208D0 (en) Medicament dispenser
GB0130284D0 (en) Medicament dispenser
GB0130857D0 (en) Medicament dispenser
GB0125134D0 (en) Medicament dispenser
GB0026647D0 (en) Medicament dispenser
HK1075619A1 (en) New uses for anti-malarial therapeutic agents
IL152593A0 (en) Liposome drug delivery
AU2002352344A8 (en) Medicament delivery assembly
GB0025092D0 (en) Medicament dispenser
AU2003211103A1 (en) Intracellular delivery of therapeutic agents
IL151910A0 (en) Compositions for drug delivery
GB0031176D0 (en) Medicament dispenser
AP2003002866A0 (en) Improved delivery of benefit agents.
AU5654701A (en) Drug delivery mask
GB0110485D0 (en) Medicament dispenser
GB0020538D0 (en) Medicament dispenser
GB0119850D0 (en) Medicament dispenser
GB0119008D0 (en) Medicament dispenser
GB0100998D0 (en) Medicament dispenser